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Abstract
Background: Alzheimer’s disease is a common debilitating dementia with known heritability, for which 20 late onset
susceptibility loci have been identified, but more remain to be discovered. This study sought to identify new susceptibility
genes, using an alternative gene-wide analytical approach which tests for patterns of association within genes, in the
powerful genome-wide association dataset of the International Genomics of Alzheimer’s Project Consortium, comprising
over 7 m genotypes from 25,580 Alzheimer’s cases and 48,466 controls.
Principal Findings: In addition to earlier reported genes, we detected genome-wide significant loci on chromosomes 8
(TP53INP1, p = 1.461026) and 14 (IGHV1-67 p = 7.961028) which indexed novel susceptibility loci.
Significance: The additional genes identified in this study, have an array of functions previously implicated in Alzheimer’s
disease, including aspects of energy metabolism, protein degradation and the immune system and add further weight to
these pathways as potential therapeutic targets in Alzheimer’s disease.
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Introduction
The prevalence of Alzheimer’s disease (AD) is increasing as
more people live into old age. Hope for finding preventative and
clinical therapies lies in the ability to gain a better understanding
of the underlying biology of the disease, and genetics will provide a
valuable starting point for advancement. Rare monogenic forms of
AD, the majority of which are attributable to mutations in one of
three genes, APP, PSEN1 and PSEN2, exist, but common, late-
onset AD is genetically complex with heritability estimated to be
between 56–79%[1,2]. Along with the APOE polymorphism[3],
20 common susceptibility loci have been identified associated with
AD[4–9]. (This figure does not include CD33 as it did not show
genome-wide significance in the original report[9].) Recently, a
moderately rare variant in TREM2 has also shown evidence for
association[10]. However, new variants remain to be found. This
study sought to identify new susceptibility genes, using an
alternative gene-wide analytical approach, which focuses on the
pattern of association within gene regions.
Genome-wide association (GWA) studies to date have focused
on single nucleotide polymorphisms (SNPs) as the unit of analysis.
Single locus tests are the simplest to generate and to interpret, but
have limitations. For example, if susceptibility is conferred by
multiple variants within a locus[11,12], this gives rise to complex
patterns of association that might not be reflected by association to
the same SNPs in different samples, despite apparently reasonably
powered tests[13,14]. In addition, rare risk-increasing variants
may not be tagged by single SNPs, as is e.g. the case for CLU in
which significant enrichment of rare variants in patients was
observed independent of the single locus GWA signal[15]. It is
therefore likely that the power to detect association might be
enhanced by exploiting information from multiple signals within
genes encompassed by gene-wide statistical approaches[12].
Disease risk may reflect the co-action of several loci but the
number of loci involved at the individual or the population levels
are unknown, as is the spectrum of allele frequencies and effect
sizes[16]. The observations of multiple genome-wide significant or
suggestive linkage signals for disorders, that do not readily
replicate between studies but which are not randomly distributed
across the genome[17,18] is compatible with the existence of
multiple risk alleles of moderate effect that would implicate a locus
in disease risk, when analysed together. Thus the first aim of this
study is to test for gene-wide association with AD, using a powerful
mega-meta analysis of genome-wide datasets as part of the
International Genomics of Alzheimer’s Project (IGAP) Consor-
tium comprising four AD genetic consortia (see the full list of
consortia members in Materials S1): Genetic and Environmental
Risk in Alzheimer’s Disease (GERAD), European Alzheimer’s
Disease Initiative (EADI), Cohorts for Heart and Aging in
Genomic Epidemiology (CHARGE) and Alzheimer’s Disease
Genetics Consortium (ADGC) (see full IGAP datasets description
in Materials S2). A two stage study was undertaken. In Stage 1 the
combined sample included 17,008 AD cases and 37,154 controls.
In Stage 2 loci with p-values (combined over all SNPs at the locus)
less than 1024 were selected for replication for 8,572 AD cases and
11,312 controls of European ancestry. We observed evidence for
gene-wide association at loci which implicate genes which already
show genome-wide significant association from single SNP analysis
(CR1, BIN1, HLA-DRB5/HLA-DRB1, CD2AP, EPHA1, PTK2B,
CLU, MS4A6A, PICALM, SORL1, SLC24A4, ABCA7, APOE), three
new genes in the vicinity of lately reported single SNP hits[9]
(ZNF3, NDUFS3, MTCH2) and two novel loci (TP53INP1,
combined p=1.461026 and IGHV1-67 combined p=7.961028).
Results
Initially, we tested for excess genetic signal revealed by the Stage
1 IGAP SNP GWAS study. We observed more SNPs at all
significance intervals, and more genes at multiple significance
thresholds, than expected by chance (Table S1). This is unlikely to
be due to uncorrected stratification, since each of the individual
GWAS samples in the IGAP Stage 1 analysis was corrected for
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" Membership of the UK Brain Expression consortium is provided in Materials S1.
Disease Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). As such, the investigators within the ADNI contributed to the design and implementation
ethnic variation. Thus it is likely that the sample contains novel
genetic signals, in addition to those detected by the primary
analysis[9,19].
Next, we looked at overrepresentation of significant genes in the
Stage 1 data. Table 1 gives the observed and expected numbers of
significant genes at significance levels 1024, 1025, 1026 when all
genes are counted in the analyses and when the known genes
(Table S1) and genes within 500kb of them are excluded, the
observed numbers of genes are much larger than expected at all
significance levels (all p#0.001). Thus there are more loci
associated with AD to find.
Furthermore, the number of independent nominally significant
loci at Stage 2 (N=60, (13.5%)) was significantly greater than
expected by chance (p= 4.6610212). The percentage of replicated
loci increased with the decrease of the gene-wise significance
threshold at Stage 1 (see Table 2 for details).
Combining the gene-wide p-values in both stages 1 and 2, using
Fisher’s method revealed two new gene-based genome-wide
significant (p,2.561026) loci TP53INP1 and IGHV1-67. The
TP53INP1 gene is located on chromosome 8:95,938,200–
95,961,615 and its combined gene-based p-value = 1.461026
(Table 3). Table S3 provides details for each SNP contributing
to the gene-based result. Out of 45 SNPs in the gene, three SNPs
(rs4735333, rs1713669, rs896855) have p-value#1024. Figure 1
shows the LD plot of this gene and suggests that there are at least
two partially independent signals in the TP53INP1 gene (r2
between the pairs of most significant SNPs rs4735333-rs1713669
and rs1713669- rs896855 are 0.65 and 0.6 respectively).
The IGHV1-67 gene on chromosome 14:107,136,620–
107,137,059 has combined p-value = 7.961028 (Tables 3). This
gene is covered by two SNPs (rs2011167, rs1961901), both are
significant at 1024 level. LD plot in Figure 2 and Table S4 indicate
that the two most significant SNPs in IGHV1-67 gene represent
almost the same signal (r2 = 0.92, calculated with SNAP
software[20], 1000 genomes Pilot 1 dataset, CEU population
panel, (http://www.broadinstitute.org/mpg/snap)).
To look at the gene expression patterns in these novel genes, we
used the Webster-Myers expression dataset[21], available at
http://labs.med.miami.edu/myers/LFuN/data%20ajhg.html.
Comparing 137 AD vs 176 controls with temporal or frontal
cortex expression values by t-test, t showed significantly higher
TP53INP1 expression in cases compared to controls (p = 0.0128).
Further examination in the BRAINEAC database[22] (www.
braineac.org) from the UK Brain Expression Consortium showed
TP53INP1 to have a best cis-eQTL p-value of 6.861026 (for
rs4582532 SNP, which is about 7.6 kb upstream of the gene). The
three SNPs with association p#1024 mentioned above
(rs4735333, rs1713669, rs896855) had significant cis-eQTL p-
values of 8.261026, 7.861025 and 1.161025 respectively in
BRAINEAC brain expression data. The r2 between the cis-eQTL
and the three associated SNPs were 0.80, 0.65, and 0.81,
respectively). Further analysis of additional independent brain
expression and methylation datasets (see Methods S1) indicated
significant cis eQTLs and meQTLs for TP53INP1 (Tables S10 and
S11). The probe for the meQTL is in a CpG island region that
corresponds well with ENCODE DNAse/ChIP-seq/Histone
marks and is located upstream (,1.5 kb) of the TP53INP1
Table 1. Overrepresentation of replication of significant genes/loci available at Stage 2, excluding all loci of 0.5 Mb around genes
previously reported[4–8] and Stage 1 IGAP genes[9,19] containing genome-wide significant SNPs.
GENES LOCI
Stage 1
significance level
Significant
at Stage 1
Replicated
(p#0.05) at Stage 2
Significant
at Stage 1
Replicated
(p#0.05) at Stage 2
Over-representation
p-value
p#1024 27 9 (33%) 9 3 (33%) 0.109
p#1023 74 17 (23%) 36 8 (22%) 0.125
p#0.01 229 49 (21%) 102 26 (25%) 0.0001
p#0.05 390 77 (20%) 171 33 (19%) 0.007
Total (p#1) 887 124 (14%) 444 60 (13.5%) 4.6610212
Over-representation p-values were calculated with chi-square/Fisher’s exact tests counting the genes within 0.5 Mb as one locus.
doi:10.1371/journal.pone.0094661.t001
Table 2. Overrepresentation of significant loci, excluding regions of 0.5 Mb around previously reported[4–8] and Stage 1 IGAP
genes[9,19] containing genome-wide significant SNPs.
Numbers of loci (genes)
p#1024 p#1025 p#1026
Observed 9(27) 4(8) 2(2)
Expected 2.5 0.25 0.025
p-value 0.001 0.00013 0.0003
The observed number of genes is calculated by combining significant loci within 0.5 Mb into one signal. The APOE region is excluded (CHR19; 44,411,940–
46,411,945bp). The total number of genes after exclusions is 24,849.
doi:10.1371/journal.pone.0094661.t002
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transcription start site. In combination these results suggest a
possible epigenetic mechanism whereby the associated variants in
the region influence TP53INP1 expression in several brain regions.
These expression data provide further evidence supporting the
functional relevance of TP53INP1 to AD susceptibility. The
IGHV1-67 gene was not found in those databases.
In addition we detected two genome-wide significant loci 1)
ZNF3 (chr7: 99,661,653–99,679,371; p= 8.661027) and 2) two
closely located genes on chromosome 11 MTCH2 (47,638,858–
47,664,206, combined p= 2.561026) and NDUFS3 (47,600,632–
47,606,114, combined p=4.861027) (Table 4). None of these
genes harbour genome-wide significant SNPs in the SNP GWAS
analysis on its own (see Tables S5-S7). Figures S1-S3 show LD
plots of these additional genes.
ZNF3 and NDUFS3, MTCH2 genes on chromosomes 7 and 11,
respectively, lie close to rs1476679 (chr7:100,004,446; ZCWPW1)
and rs1083872 (chr11:47,557,871; CELF1) SNPs, which are shown
to be genome-wide significant in the IGAP study, when combining
Stage 1 and Stage 2 data. Figures S1-S3 show LD structure of
these genes in relation to the IGAP singe genome-wide significant
hits. (Note that the NDUFS3 gene on chromosome 11 was gene-
based genome-wide significant already at Stage 1.) Although none
of these SNPs actually lie within the genes mentioned above, it is
possible that they may account for the gene-based signals through
linkage disequilibrium. In order to test whether the gene-based
signals are independent of these strongly-associated SNPs, we
performed single-SNP association for each SNP annotated to these
genes by regression, adjusting for the significant SNPs mentioned
above, along with the other study covariates. The resulting p-
values were combined into gene-based tests, as described
previously. Under this conditional analysis ZNF3 gene does not
show significant association, however NDUFS3 still shows a trend
towards significance (p = 0.081) (see Table S8 for details).
Furthermore, five genes in chr11:47,593,749–47,615,961
(KBTBD4, NDUFS3, LOC100287127, FAM180B, C1QTNF4) all
have p,0.05 with gene-based analysis 610 kb, when conditioning
by the genome-wide significant hit rs10838725 in this region. This
may partially be explained by the SNP rs10838731 (p = 1.261023
after conditioning by rs10838725) which is shared by all latter five
genes.
Gene-based analysis with 610 kb around genes did not reveal
additional genome-wide significant loci in the Stage 1 data set.
Moreover, the significance of the genes identified above did not
improve in general, indicating that adding 10 kb flanking regions
to genes introduces more noise to the gene-based signal. The
combined Stage 1 and Stage 2 gene-based analysis provided
further evidence for significant signals in the loci on chr 11 with 8
genes (SPI1, SLC39A13, LOC100287086, PTPMT1, KBTBD4,
NDUFS3, LOC100287127, FAM180B) and on chr 7 with 6 genes
(LOC100128334, MCM7, PILRB, PILRA, LOC100289298,
C7orf51), all reaching genome-wide significance. This is likely to
be due to the fact that including genes’ flanking regions captures a
greater number of the same SNPs or SNPs in high LD showing
significant association.
The Manhattan plot of the gene-based p-values (Figure 3) gives
a general overview of the gene-based results and shows the new
loci in relation to previously reported genes (see also QQ-plots in
Figure S4). The results of gene-wide analysis for the genes, which
were previously reported as associated with AD[4-8] and those
which are GWAS significant in the Stage 1 analysis are presented
in Table S9. Out of 16 reported susceptibility genes, 15 are
nominally significant with gene-wide analysis (almost all p-values
are smaller than 1024), however not all of them reach the gene-
based genome-wide significance level (2.561026) when the
number of SNPs per gene and LD structure of the gene is taken
into account.
Figure 1. Linkage disequilibrium structure of TP53INP1 gene. The SNPs which are significant at 1024 level are circled in red.
doi:10.1371/journal.pone.0094661.g001
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We did not observe genome-wide significance for CD33 gene.
This gene was genome-wide significant in Stage 1 (p = 1.961026),
but the association was attenuated when combining Stage 1 and
Stage 2 data (p = 1.7961025), similar to the single SNP association
result in the SNP GWAS study[9,19].
Discussion
In this study we show that there are more signals in the GWAS
imputed data at SNP- and gene-based levels than revealed by
single SNP analysis. A gene-based analysis is a next logical step
after the single SNP analyses in any attempt to combine possible
several signals in genes and thus enhance the power of the
association analyses.
The first new gene TP53INP1 (chromosome 8) encodes a
protein that is involved in mediating autophagy-dependent cell
death via apoptosis through altering the phosphorylation state of
p53[23] and in modulating cell-extracellular matrix adhesion and
cell migration[24]. TP53INP1 encodes a pro-apoptotic tumor
suppressor and its antisense oligonucleotide has been used as
potential treatment for castration-resistant prostate cancer[25].
This association is notable, given the potential inverse association
between cancer and AD that has previously been reported [26,27].
The second new gene IGHV1-67 (chromosome 14) is a
pseudogene in the immunoglobulin (IgG) variable heavy chain
region of chromosome 14: its function is unknown but all genes in
this region are most likely to be involved in IgG heavy chain VDJ
recombinations that lead to the full repertoire of antigen-detecting
immune cell clones[28].
The gene-based analysis in this study has shown its utility to
enhance the information provided by single SNP analysis (i.e.
NDUFS3 gene was genome-wide significant from Stage 1 using
gene-based analysis whereas this gene was only genome-wide
significant after combining the two stages of single SNP analysis).
ZNF3 is a zinc-finger protein at the same locus on chromosome
7 as ZCWPW1 thus rendering it a candidate as the gene that
contains the functional signal in this region. Although we can not
identify which gene actually confers the risk to AD, it is interesting
that ZNF3 function is unknown though it interacts with BAG3
which is involved in ubiquitin/proteasomal functions in protein
degradation[29] and ZNF3 is regulated by upstream binding of
BACH1 whose target genes have roles in the oxidative stress
response and control of the cell cycle[30].
In the cluster of genes on chromosome 11,MTCH2 encodes one
of the large family of inner mitochondrial membrane transport-
ers[31] which is associated with mitochondrially-mediated cell
death[32], adipocyte differentiation[33], insulin sensitivity[34] and
has a genetic association with increased BMI[35]. NDUFS3 also
has functions in the mitochondria as it encodes an iron-sulphur
component of complex 1 (mitochondrial NADH:ubiquinone
oxidoreductase) of the electron transport chain. A deficiency
causes a form of Leigh syndrome[36] an early-onset progressive
neurodegenerative disorder with a characteristic neuropathology
consisting of focal lesions including areas of demyelination and
gliosis[37].
In summary, we report two novel genes TP53INP1 (chr8:
95,938,200–95,961,615; combined p= 1.461026) and IGHV1-67
(chr14: 107,136,620–107,137,059; combined p=7.961028),
which were not reported as genome-wide significant before. We
also report ZNF3 gene on chromosome 7 and a cluster of genes on
chromosome 11 (SPI1-MTCH2), showing gene-based genome-
wide significant association with Alzheimer’s disease. These genes
are in proximity with, but not the same as, those detected by
genome-wide significant SNPs, demonstrating support for the
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signals identified by IGAP[9,19]. They have an array of functions
previously implicated in AD including aspects of energy metab-
olism, protein degradation and the immune system and add
further weight to these pathways as potential therapeutic targets in
AD.
Materials and Methods
Stage 1 data
The main dataset was reported by the IGAP consortium[9,19]
and consists in total of 17,008 cases and 37,154 controls. This
sample of AD cases and controls comprises 4 data sets taken from
genome-wide association studies performed by GERAD, EADI,
CHARGE and ADGC (see primary IGAP manuscript[9,19] for
more details). The full details of the samples and methods for
conduct of the GWA studies are provided in the respective
manuscripts[4-8].
Each of these datasets was imputed with Impute2[38] or
MACH[39] software using the 1000 genomes data (release
Dec2010) as a reference panel. In total 11,863,202 SNPs were
included in the SNPs allelic association result file. To make our
analysis as conservative as possible, we only included autosomal
SNPs which passed stringent quality control criteria, i.e. we
included only SNPs with minor allele frequencies (MAF) $0.01
and imputation quality score greater than or equal to 0.3 in each
individual study, resulting in 7,055,881 SNPs which are present in
at least 40% of the AD cases and 40% of the controls in the
analysis. The summary statistics across datasets were combined
using fixed-effects inverse variance-weighted meta-analysis. We
corrected all individual SNPs p-values for genomic control (GC)
l=1.087. These SNPs are well imputed on a large proportion of
the sample, which increases confidence in the accuracy of the
association analysis upon which gene-wide analysis is based.
Stage 2 data
11,632 SNPs with p-values ,1023 in the IGAP meta-analysis
were successfully genotyped in a Stage 2 sample comprising 8,572
cases and 11,312 controls (see primary IGAP manuscript[9,19]
for more details). An additional 771 SNPs were successfully
genotyped to test all genes with gene-wide p-values ,10-4 in the
IGAP Stage 1 analysis, excluding genes reported prior to
IGAP[4–8], the four loci reaching genome-wide significance in
the Stage 1 IGAP meta-analysis[9,19] and the 0.5Mb regions
around them (Table S2). These SNPs cover 887 genes and
correspond to 444 independent loci where all genes within
0.5 Mb are counted as one locus.
Assignment of SNPs to genes
SNPs were assigned to genes if they were located within the
genomic sequence lying between the start of the first and the end
of the last exon of any transcript corresponding to that gene. The
chromosome and location for all currently known human SNPs
were taken from the dbSNP132 database, as was their assignment
to genes (using build 37.1). In total, we retained 2,804,431 (39.7%
of the total) SNPs which annotated 28,636 unique genes with 1–
16,514 SNPs per gene. For the gene-wide analysis we have
excluded genes which contain only one SNP in the IGAP Stage 1
analysis, leaving a total of 25,310 genes. If a SNP belongs to more
than one gene, it was assigned to each of these genes. In order to
account for possible signals which are correlated with those in a
gene, gene-wide analysis was also performed using a 10 kb window
around genes to assign SNPs to genes.
Figure 2. Linkage disequilibrium structure of IGHV1-67 gene ±5 kb. The SNPs which are significant at 1024 level are circled in red.
doi:10.1371/journal.pone.0094661.g002
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Gene-wide analysis
The gene-wide analysis was performed based on the summary
p-values while controlling for LD and different number of markers
per gene using an approximate statistical approach[40] adopted
for set-based analysis of genetic data[41]. This is a method for
calculating the significance of a set of SNPs in the absence of
individual genotype data based on a theoretical approximation to
Fisher’s statistic for combining p-values. Fisher’s statistic (-gln(pi))
combines probabilities and under the null hypothesis has a chi-
square distribution with 2N degrees of freedom, where N is the
number of markers, and the summation above is for i =1,…,N). If
Fisher’s statistic combines the results of several tests when the tests
are independent, the approximate method combines non-inde-
pendent tests and requires only the list of p-values for each SNP
and knowledge of correlations between SNPs. Then the value of
Fisher’s statistic and the number of degrees of freedom is corrected
by the coefficient which depends upon the number of SNPs and
correlations (LD) between them. This approximation was applied
to the Stage 1 and Stage 2 samples separately, and the resulting
gene-wide p-values combined using Fisher’s method (since these
are independent). LD between markers was computed using 1000
genomes data. The gene-based genome-wide significant level was
set to 2.561026 to account for the number of tested genes[42].
Test for excess of associated SNPs/loci
The effective number N of independent SNPs in the whole
genome (excluding genes with SNPs that are genome-wide
significant in the Stage 1 IGAP dataset 6 0.5 Mb was estimated
by the method described in [43] taking LD into account, as were
the observed number of independent SNPs significant at each p-
value criterion (adjusting individual SNP p-values for genomic
control l=1.087 before hand). LD was computed from the 1000
Genomes database (http://www.1000genomes.org/). In the
absence of excess association, the expected number of independent
SNPs significant at significance level a is a normally distributed
random variable whose mean and standard deviation (SD) can be
calculated as aN and !Na(1-a) (mean and SD for a binomial
distribution). The number of independent SNPs (and thus
statistical tests) in the whole genome were estimated as
,3.76106, ,3.66106 and ,3.56106 at significance levels below
0.1, between 0.05 and 0.1, and 0.2 and above respectively (see [43]
for details on the dependence between the significance levels and
the estimated number of independent tests). We then calculated
mean of the expected number of significant SNPs in intervals a1 ,
p # a2, (a1, a2 = 0, 10
26, 1025, …, 0.5) as difference between the
expected numbers of independent SNPs at a2 and a1 significance
levels and SD as the square root of sum of the corresponding
variances.
We calculated the significance of the excess number of genes
attaining the specified thresholds based upon the assumption that,
under the null hypothesis of no association, the number of
significant genes at a significance level of a in a scan is distributed
as a binomial (N,a), where N is the total number of genes, assuming
that genes are independent. Genes within 0.5 Mb of each other
are counted as one signal when calculating the observed number
of significant genes. This prevents significance being inflated by LD
between genes, where a single association signal gives rise to
several significantly-associated genes. The total number of genes
was not corrected for LD in this way, making the estimate of
significance of the excess number of genes conservative.
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Supporting Information
Table S1 Overrepresentation of significant SNPs ex-
cluding previously reported[4-8] genes ±0.5Mb and the
APOE region as above.
(DOCX)
Table S2 List of genes that are genome-wide significant
in the IGAP stage 1 dataset and the flanking regions
which included SNPs either in r2$0.3 or association p-
value#10-3 whichever covers the largest region.
(DOCX)
Table S3 Detailed SNP information for TP53INP1 gene.
(XLS)
Table S4 Detailed SNP information for IGHV1-67 gene.
(XLS)
Table S5 Detailed SNP information for ZNF3 gene.
(XLS)
Table S6 Detailed SNP information for NDUFS3 gene.
(XLS)
Table S7 Detailed SNP information for MTCH2 gene.
(XLS)
Table S8 Gene-based analysis results, when single
SNPs p-values, contributing to the gene-based p-value
were adjusted for the best genome-wide significant SNP
in the nearby location.
(DOCX)
Table S9 Gene-wide analysis for genes which show
GWAS significant association with AD in the stage 1
IGAP dataset.
(DOCX)
Table S10 Brain eQTL Tissues.
(XLSX)
Table S11 Brain Meth QTLs.
(XLSX)
Figure S1 ZNF3 gene with rs1476679 (ZCWPW1) report-
ed by Lambert et al (2013) study. SNPs which are significant
at 1e-3 level are circled in red, rs1476679 is highlighted in blue.
(TIF)
Figure S2 NDUFS3 gene rs10838725 (CELF1) reported by
Lambert et al (2013) study. SNPs which are significant at 1e-3
level are circled in red, rs10838725 is highlighted in blue.
(TIF)
Figure S3 MTCH2 gene with rs10838725 (CELF1) re-
ported by Lambert et al (2013) study. SNPs which are
significant at 1e-3 level are circled in red, rs10838725 is
highlighted in blue.
(TIF)
Figure S4 QQ-plot of gene-wide p-values for all genes
(A) and excluding previously reported[4-8] GWAS signif-
icantly associated genes ±0.5Mb (B) in the discovery
dataset. Genomic control l=1.08 and 1.07 respectively.
(TIFF)
Methods S1 Expression quantitative trait loci (eQTL) and
Methylation quantitative trait loci (meQTL) analyses.
(DOCX)
Materials S1 Full IGAP datasets description.
(DOCX)
Materials S2 List of IGAP consortium members.
(DOC)
Figure 3. Manhattan plot of gene-wide p-values in the Stage 1 dataset and combined gene-wide p-values where Stage 2 data are
available. Each dot represents a gene, genes in blue lie within the previously reported[4–8] associated regions.
doi:10.1371/journal.pone.0094661.g003
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